King Pharmaceuticals KG Increase (Decrease) in Premiums Receivable
Increase (Decrease) in Premiums Receivable at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPremiumsReceivable.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's increase (decrease) in premiums receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is King Pharmaceuticals's increase (decrease) in premiums receivable?
- King Pharmaceuticals (KG) reported increase (decrease) in premiums receivable of -$373K in Q1 2026.
- What does increase (decrease) in premiums receivable mean?
- The net change in premiums owed to the company by policyholders during the reporting period. An increase indicates that more premiums have been billed but not yet collected, which can impact short-term liquidity. This metric is a key indicator of the efficiency of the company's premium collection process and credit risk management.